Evaxion A/S EVAX
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- -38.57%
- 1 year
- -49.13%
- Open
- 3.11
- Prev close
- 3.08
- Mkt cap
- 26.43M
- Vol
- 46.20K
- Avg vol
- 233.92K
- EPS
- -1.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 2.89
- High
- 3.16
- Forward P/E
- -0.72
- Beta
- -0.23
- Short ratio
- 0.75
- Inst. own
- 9.90%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 14, 2024
- 50-d avg
- 1.95
- 200-d avg
- 2.95
- 1y target
- 11.56
3M chart
Signals (31)
| Name | Date | Ago |
|---|---|---|
| MACD: Sell Signal | Oct 28, 2026 | 4 days ago |
| SMA: Bearish | Oct 26, 2026 | 6 days ago |
| SMA: Bearish | Oct 26, 2026 | 6 days ago |
| MACD: Buy Signal | Oct 20, 2026 | 1 week ago |
| RSI: Overbought | Oct 20, 2026 | 1 week ago |
| SMA: Bullish | Oct 19, 2026 | 1 week ago |
| SMA: Bullish | Oct 19, 2026 | 1 week ago |
| RSI: Oversold | Oct 13, 2026 | 2 weeks ago |
| SMA: Bearish | Oct 8, 2026 | 3 weeks ago |
| SMA: Bearish | Oct 5, 2026 | 3 weeks ago |
| SMA: Bullish | Oct 2, 2026 | 1 month ago |
| MACD: Sell Signal | Oct 2, 2026 | 1 month ago |
| SMA: Bearish | Oct 1, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 18, 2026 | 1 month ago |
| SMA: Bullish | Sep 17, 2026 | 1 month ago |
| SMA: Bullish | Sep 17, 2026 | 1 month ago |
| SMA: Bearish | Sep 14, 2026 | 1 month ago |
| SMA: Bearish | Sep 14, 2026 | 1 month ago |
| SMA: Bullish | Sep 11, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 11, 2026 | 1 month ago |
| SMA: Bearish | Sep 10, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 9, 2026 | 1 month ago |
| SMA: Bullish | Sep 4, 2026 | 1 month ago |
| SMA: Bearish | Aug 28, 2026 | 2 months ago |
| SMA: Bearish | Aug 28, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 28, 2026 | 2 months ago |
| SMA: Bullish | Aug 20, 2026 | 2 months ago |
| SMA: Bearish | Aug 17, 2026 | 2 months ago |
| SMA: Bullish | Aug 13, 2026 | 2 months ago |
| SMA: Bullish | Aug 7, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 4, 2026 | 2 months ago |
Key statistics
- Market cap
- 5.32M
- Enterprise value
- 46.26M
- Trailing P/E
- 0.00
- Forward P/E
- -0.72
- PEG ratio
- 0.00
- Price / sales
- 1.62
- Price / book
- 69.82
- EPS (TTM)
- -2.80
- Beta
- -0.23
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 3.29M
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 4.58M
- Total debt
- 0
- Return on equity
- 0.00%
- Shares outstanding
- 5.87M
- Short % of float
- 0.74%
- 50-day average
- 1.95
- 200-day average
- 2.95
Analyst view
Consensus: none
- Target (low)
- 7.00
- Target (mean)
- 11.56
- Target (high)
- 18.00
- Strong buy1
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 14, 2024
Expected Aug 14, 2024. Consensus EPS estimate -0.03.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Oct 31, 2024 | Sep 1, 2024 | -0.12 | -0.04 | +0.08 | +66.67% |
| Aug 14, 2024 | Jun 1, 2024 | 0.02 | — | — | — |
| Aug 14, 2024 | Jun 1, 2024 | 0.02 | -0.12 | -0.14 | -700.00% |
| May 28, 2024 | Mar 1, 2024 | 0.00 | — | — | — |
| May 28, 2024 | Mar 1, 2024 | 0.00 | 0.03 | — | — |
| Mar 27, 2024 | Dec 1, 2023 | 0.00 | -0.16 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 1, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Sep 26, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Sep 20, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 16, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 1, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Jun 4, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About Evaxion A/S
Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers. Its programs also include some vaccines that are in pre-clinical stage, which includes EVX-B1 for the prevention of S. aureus-induced skin and soft tissue infections in patients undergoing elective abdominal hernia surgery; EVX-B2 to target diseases caused by N. gonorrhoeae; EVX-B3 for eliciting strong humoral antibody and cellular immune response to the bacterial pathogen; and EVX-V1, viral vaccine product candidate for targeting Cytomegalovirus. Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Denmark
- Website
- evaxion-biotech.com
News
- Evaxion receives International Prix Galien Award for AI-Immunology™ as best digital health solution
- Evaxion A/S (EVAX) Discusses EVX-01 Phase II Clinical and Immune Data in Advanced Melanoma Transcript
- Evaxion A/S (NASDAQ:EVAX) Shares Break Below 200 Day Moving Average – What’s Next?
- 12 Health Care Stocks Moving In Friday's Pre-Market Session
- Evaxion Reports All Patients Maintained Clinical Response With No Tumor Progression Through Year Three Of EVX-01 Monotherapy In Advanced Melanoma Phase 2 Trial, 89% Of Vaccine Neoantigens Triggered T-Cell Responses
- Evaxion announces 89% vaccine target precision and sustained T-cell and clinical responses at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01
- Evaxion reports sustained clinical responses for all patients at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01
- 12 Health Care Stocks Moving In Friday's Pre-Market Session
- 12 Health Care Stocks Moving In Monday's Pre-Market Session
- Evaxion will present new immune data for personalized cancer vaccine EVX-01 at the SITC 2026 Annual Meeting
Your note
Sign in to keep a note on EVAX — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Armistice Capital, LLC | 8.23% | 483,000 | 438.42K | Sep 29, 2024 |
| Invst, LLC | 0.74% | 43,200 | 39.21K | Sep 29, 2024 |
| Citadel Advisors Llc | 0.25% | 14,825 | 13.46K | Sep 29, 2024 |
| Beacon Capital Management, LLC | 0.08% | 4,863 | 4.41K | Sep 29, 2024 |
| Blackrock Inc. | 0.03% | 1,512 | 1.37K | Sep 29, 2024 |
| JP Morgan Chase & Company | 0.01% | 780 | 708 | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 0.06% | 3,348 | 3.04K | Oct 30, 2024 |